For in vitro diagnostic use.
More than 1.4 million new prostate cancer cases were diagnosed in 2022.1
Prostate cancer is the 4th most common cancer overall.2
About 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40.3
Prostate cancer accounts for about 15% of cancers in men worldwide.
It is predicted that the global burden of prostate cancer is set to more than double to almost three million new cases by 2040, compared with the estimated number of cases today.4
= 100,000 cases
= 100,000 new cases
Prostate screening may help identify prostate cancers early, allowing for timely treatment. Survival rates are highest when prostate cancer is caught early.5
Many men have an annual blood test with their primary care provider called a PSA test that stands for “prostate specific antigen” as well as a prostate examination.
Screening: If PSA levels are normal, a clinician will determine screening protocols for each patient.
If the Total PSA test yields abnormal results, subsequent actions may involve repeating the test, conducting secondary tests such as Free PSA, and/or proceeding with imaging before considering a biopsy.
A biopsy is needed to confirm prostate cancer diagnosis.
A clinician will provide treatment plans based on the presence of and stage of cancer.
A PSA test will be used to monitor disease and recurrence.
This webinar showcases two experts who provide a comprehensive understanding of the burden of prostate cancer, highlight the disparities of prostate cancer among different races and ethnicities, and emphasize the pivotal role of biomarkers. Total PSA is a screening test aiding in the diagnosis of prostate cancer. Secondary tests such as Free PSA can aid in discriminating between prostate cancer and benign disease, helping to optimize the patient journey.
Aid in detection of prostate cancer8
Monitor disease progression and treatment response8
Identify disease recurrence8
Total PSA test
>4 and <10 ng/mL
Free PSA Test
The percent-free PSA (%fPSA) test helps determine the likelihood of prostate cancer by comparing the ratio of free to total PSA, with lower ratios indicating a higher risk and the potential need for a biopsy.
3a. based on
<10% fPSA
3b. based on
10–25% fPSA
3c. based on
>25% fPSA
Authors summarize prostate biomarkers and their clinical performance to aid in the diagnosis and management of prostate cancer.
| Publication | Description |
| The study discusses the occurrence of the hook effect in immunoassays in total PSA and total hCG with different immunoassay analyzers. The authors also compared the sensitivity of different immunoassay analyzers. | |
| The study aimed to determine if a total PSA combined with percent free PSA (%fPSA) could help risk-stratify men for screening and enhance diagnostic accuracy for clinically significant prostate cancer and fatal prostate cancer using data from the PLCO* Screening trial. |
Abbott's high-quality immunoassay menu helps laboratories meet requirements to be reliable, accurate and precise.
Learn about Abbott's biomarkers for ovarian cancer focusing on CA 125 and HE4 for early detection and monitoring.
Discover how Alinity uses powerful technology to help redefine and improve operational productivity and confidence in your laboratory.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
